Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.10
+0.29 (4.19%)
At close: Jun 18, 2026, 4:00 PM EDT
7.09
0.00 (-0.07%)
After-hours: Jun 18, 2026, 7:08 PM EDT
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$37,750
Profits / Employee
-$1,092,882
Market Cap
255.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Adagene | 128 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Zentalis Pharmaceuticals | 106 |
| Orchestra BioMed Holdings | 86 |
| Armata Pharmaceuticals | 61 |
| Fulcrum Therapeutics | 55 |
TRDA News
- 8 days ago - Entrada Therapeutics Transcript: AGM 2026 - Transcripts
- 10 days ago - Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim - TheFly
- 10 days ago - Entrada Therapeutics Slides: Corporate presentation - Filings
- 15 days ago - Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 16 days ago - Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study - GlobeNewsWire
- 17 days ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts